All In MedTech

FDA Clearance Tracker · P010015-S215

CONSULTA CRT-P, SYNCRA CRT-P

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 14, 2014 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 14, 2014

Approved

Time to decision

175 days

Received Aug 23, 2013. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P010015-S215
Device name
CONSULTA CRT-P, SYNCRA CRT-P
Applicant location
Mounds View, MN
Received
Aug 23, 2013
Decided
Feb 14, 2014
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P010015

Device type

Device class
Class III

Every decision under product code NKE

FDA's approval statement

As written in FDA's record.

APPROVAL FOR UPDATES TO THE MEDTRONIC MYCARELINK PATIENT MONITOR MODEL24950, READER MODEL 24955, AND ACCESSORIES, MODEL 2491 DEVICE DATA MANAGEMENT APPLICATION (DDMA) AND APPLICATION SOFTWARE SW026 TO SUPPORT MEDTRONIC¿S REVEAL LINQ INSERTABLE CARDIAC MONITORS (ICM).

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.